Pioglitazone and clarithromycin combined with metronomic chemotherapy vs. nivolumab in patients with advanced non-small-cell lung cancer: Outcomes from a randomized phase II trial (ModuLung)
![](/sites/default/files/styles/news_article/public/2023-06/esmo-2019-banner.jpg?h=4fe9579d&itok=8bGeGE7W)
Pioglitazone and clarithromycin combined with metronomic chemotherapy vs. nivolumab in patients with advanced non-small-cell lung cancer: Outcomes from a randomized phase II trial (ModuLung)
Read more on the Modulung trial here